Here we describe a collaboration between industry, the National Health Service (NHS) and 14 academia that sought to demonstrate how early understanding of both pharmacology and 15 genomics can improve strategies for the development of precision medicines. Diseased tissue 16 ethically acquired from patients suffering from chronic obstructive pulmonary disease 17 (COPD), was used to investigate inter-patient variability in drug efficacy using ex vivo 18 organocultures of fresh lung tissue as the test system. The reduction in inflammatory cytokines 19 in the presence of various test drugs was used as the measure of drug efficacy and the individual 20 patient responses were then matched against genotype and microRNA profiles in an attempt to 21 identify unique predictors of drug responsiveness. Our findings suggest that genetic variation 22 in CYP2E1 and SMAD3 genes may partly explain the observed variation in drug response. 23
Introduction
benefit from common medications, most likely due to the combination of variations in disease 69 subtype and genotype. The clinical variation in drug response is apparent in ex vivo 70 pharmacology experiments using fresh lung tissues 29 . 71 In this project, diseased tissue ethically acquired from patients suffering from COPD, was used 72 to investigate inter-patient variability in drug efficacy using ex vivo organocultures of fresh 73 lung tissue as the test system. In order to assess patient variation and responsiveness to both Method 91 COPD lung parenchyma tissue was ethically obtained from 25 patients undergoing therapeutic 92 resection for cancer or COPD. Residual tissue, not required for diagnosis, was acquired from 93 NHS Research Scotland Bio-repository Network and also through the REPROCELL tissue 94 network. Patients provided written consent, complying with the declaration of Helsinki. 95 Lung parenchyma was dissected free from pleura, visible airways and blood vessels to produce 96 5 mm 3 biopsies. Two biopsies were immediately placed in RNAlater and stored at 2 to 8C 97 overnight, prior to storage at -80C. Remaining biopsies were subjected to the following 98 culture protocol. 99 RPMI 1640 culture medium was prepared by adding the following constituents: gentamicin 100 (100 µg/ml), amphotericin B (0.625 µg/ml), FBS (0.5%), retinyl acetate (0.1 µg/ml), bovine 101 insulin (1 µg/ml) and nystatin (1 µg/ml). Final concentration of each constituent is displayed.
102
Biopsies were submerged in culture media (two biopsies per well) and incubated for 16 to 24h 103 at 37 C, in the presence of 5% CO2.
104
Following the incubation period, media was refreshed and each well containing two biopsies 105 was exposed to LPS (100 ng/ml), in an attempt to boost and normalise inter-biopsy 106 inflammatory cytokine release. Each well was assigned one of the following experimental 107 conditions: DMSO vehicle; roflumilast (100 nM); fluticasone (1 µM); formoterol (10 nM); or 108 a combination of roflumilast (100 nM) plus fluticasone (1 µM) or formoterol (10 nM). Biopsies 109 were then subjected to a further incubation period of 24 h at 37 C in the presence of 5% CO2.
110
Culture supernatants were sampled from each well, protease inhibitor added to prevent 111 degradation of inflammatory cytokines and stored at -80C prior to analysis.
112
Each experimental condition was performed in duplicate culture wells. Levels of TNFα (pg/ml) were measured in culture supernatants using a magnetic bead-based 115 assay for the Luminex MAGPIX platform. Fluorescence levels correlating with TNFα level 116 were corrected against the blank control level and a standard curve was generated using a 5-117 parameter logistic equation.
118
Each culture supernatant sample was analysed in duplicate and reported by Bio plex Manager 119 6.1 software as mean TNFα concentration (pg/ml), along with standard deviation of the mean 120 and the percentage coefficient of variation.
121
Graph Pad Prism 4 software was used to display the data for all 25 donors as a median or mean 122 TNFα concentration (pg/ml) + Standard Error of Mean (SEM.).
123
Median and mean TNFα concentration was also displayed in Graph Pad Prism 4 as a percentage 124 of DMSO vehicle control.
125

RNA, DNA extraction and miRNA analysis -Sistemic
126
Two baseline lung biopsies were prepared from 25 donors, as described above, and transported 127 to Sistemic for DNA and RNA extraction. TNFα levels (pg/ml) for each experimental condition were normalised using log2 ratios against 185 DMSO vehicle control. Relative levels of TNFα were then visualised using bar charts, density 186 plots and correlation plots within R software. The aim was to identify subgroups of patients 187 that displayed a good reduction of TNFα levels in response to one or more of the organoculture 188 experimental conditions and subgroups of patients that displayed a poor reduction.
189
Patients were then categorised as being a high responder or a low responder for use in The genotype for all SNPs identified from the VCF file was tested for association with the 210 organoculture assay response, this was performed using fisher-exact tests of association within 211 the Plink analysis toolkit 31 . Identified SNPs included those that were known to be related to 212 genes of interest and also novel, undescribed SNPs.
213
Genes of interest were identified due to a literature association with the pathology of COPD 214 and/or as being associated with lung metabolism and/or genes that may be associated with 215 clinical response to standard of care treatments. 
242
In the same way, miRNA target genes were analysed for enrichment of gene ontology terms. The majority of COPD patient lung samples responded to treatment with fluticasone, 252 roflumilast or combination therapy. This was observed as a reduction in the level of TNFα 253 released from the biopsies into the culture media (Fig 2) . Different levels of response were 254 however observed between patients and ranged from modest to a marked reduction in TNFα in 255 the supernatant. (Fig 4) . 12 patient samples were categorised as being high responders and 13 as 270 low responders to the roflumilast plus fluticasone treatment.
271
Organoculture Bioinformatics
272
All patient samples passed quality control analysis as described above. Fisher's exact test, performed in the Plink toolkit, showed that no genotypes corresponding 317 with the identified SNPs were significantly associated with the organoculture response.
318
However, to allow a very tentative interpretation of the results, and taking into account the low 319 number of patients studied, an uncorrected p-value of <0.001 was chosen. With this approach 320 a total of 30 SNPs, corresponding to 23 genes, were found to correlate with the level of TNFα CYP2E1 is an inducible drug metabolising enzyme expressed in human lung tissue and has 325 been implicated in pathological oxidative stress 21, 22 . Expression of other CYP2E1 SNPs 326 including rs3737034 and rs2249695 were also shown to correlate with patient organoculture 327 response. The significance level was however borderline as determined in the bioinformatic 328 analysis (p 0.008/0.01).
329
Our findings suggest that genetic variation in the cytochrome p450 enzyme (CYP2E1) gene, 330 namely SNP (rs2249695), may partly explain the observed variation in drug response. Biopsies 331 from patients who had at least one copy of the reference allele for this SNP generally responded 332 better to roflumilast and fluticasone co-treatment. As shown in Figure 5 , mean TNFα release 333 was inhibited by 77.6 % (homozygous reference genotype (TT)) and by 50.74 % (homozygous 334 alternative genotype (CC)). Levels of inhibition between these two genotypes were found to 335 be significantly different with a p value of 0.02 (unpaired, two-tailed t-test). The homozygous 336 reference haplotype has been associated with low CYP2E1 expression 33 .
337
Genetic variation in Mothers against decapentaplegic homolog 3 (SMAD3) gene was also 338 found to relate to patient organoculture response. As shown in Figure 6 , mean TNFα release 339 was inhibited by 66% (homozygous alternative genotype (GG)) and by 39% (heterozygous 340 genotype). Levels of inhibition between these two genotypes were found to be significantly 341 different with a p value of 0.0054 (unpaired, two-tailed t-test). Only two patient samples were 342 found to have the homozygous reference haplotype (AA) and mean TNFα release was inhibited 343 by 54 % in this group of patient samples. This level of inhibition was not significantly different 344 to the homozygous alternative genotype or the heterozygous genotype. RNA quality control analysis showed that isolated RNA was of high purity, 260/280 ratios 368 ranged from 1.8 to 2.0 and RNA integrity scores ranged from 5.8 to 7.8.
369
All patient samples, except one, passed Agilent miRNA array quality control analysis with a 370 rating of good to excellent. The remaining sample was flagged for evaluation and removed 371 from subsequent bioinformatic analysis. 372 Statistical analysis showed that there were no specific differences in miRNA expression 373 detected in patients that responded well in the organoculture assay compared with patients that 374 did not respond. This analysis was performed using a p-value that had been adjusted for 375 multiple statistical testing. For the purposes of this exemplar study, a relaxed p-value 376 (uncorrected p <0.05) was subsequently applied. At this threshold, 181 miRNAs, mapping to 377 636 genes, were found to be differentially expressed in COPD patient samples that were high 378 responders to roflumilast plus fluticasone treatment compared with samples that showed a poor 379 response. 86 miRNAs were found to be upregulated, correlating with 47 KEGG pathways that 380 reached statistical significance. This Enrichment analysis highlighted KEGG pathways 381 associated with TGF-β signalling, synaptic function and fatty acid metabolism. 382 95 miRNAs were found to be down regulated correlating with 4 KEGG pathways that reached 383 statistical significance. This Enrichment analysis highlighted KEGG pathways associated with 384 long-term depression and serotonergic and GABAergic synaptic function. 385 1,610 GO terms were significantly associated with up-regulated miRNAs and found to be 386 significantly enriched for pathways associated with cell ageing, specifically telomerase 387 activity. Pathways involved in synaptic activity and T cell differentiation were also found to 388 be upregulated. 389 310 GO terms were significantly associated with down-regulated miRNAs and found to be 390 significantly enriched for pathways associated with B cell receptor activity and TGF-β 391 production.
392
As discussed, bioinformatic analysis identified 30 SNPs corresponding to 23 genes (p <0.001) 393 and 181 miRNAs (mapping to 636 genes, p <0.05) as being related to organoculture response. 394 With further relaxation of the exome analysis p value to 0.01congruence analysis found that a 395 total of 10 genes overlapped between the exome sequence and miRNA expression data and this 396 overlap is higher than would be expected by chance. Overlapping genes are NTN4, IGF1R, 
